Physicians' Academy for Cardiovascular Education

Fewer CV events but higher risk of amputation with SGLT2 inhibitor in T2DM patients

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Literature - Neal B, Perkovic V, Mahaffey KW, et al, for the CANVAS Program Collaborative Group - NEJM 2017; published online ahead of print

Main results


In the CANVAS trial program, diabetic patients with elevated CV risk treated with canagliflozin had a significantly lower risk of CV death, non-fatal MI, or non-fatal stroke compared with those who received placebo, but a higher risk of amputation and fractures.


Show references

Find this article online at NEJM

Share this page with your colleagues and friends: